Johnstone Peter A S, Kerstiens John
Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana; Indiana University Health Proton Therapy Center, Bloomington, Indiana.
Indiana University Health Proton Therapy Center, Bloomington, Indiana.
J Am Coll Radiol. 2014 Oct;11(10):995-7. doi: 10.1016/j.jacr.2014.04.004. Epub 2014 Jun 2.
Proton beam therapy (PBT) is the most expensive form of radiation therapy in the United States. An area in which clear advantage has been modeled is the use of PBT for pediatric patients, although no publications deal with practice costs to PBT centers associated with a pediatric focus. Pediatric cases require longer treatment times and more staff members and incur higher supply and device costs. In addition to being more expensive to treat, the pediatric patients at the authors' center also present with Medicaid as their primary insurer at higher rates than adults. At their center, in the past 2 years, pediatric patients (<21 years of age) have constituted 32% of total patients treated. The authors present their cost experience in a PBT environment treating a large number of children.
After approval was obtained from the local institutional review board, data relating to patients ≤21 years of age who started treatment during the period between November 1, 2011, and October 31, 2013, were reviewed. Direct expenses of devices and supplies used, billing for anesthesia, staffing, and direct operational costs (proton beam) were calculated to determine the direct cost to treat. Those direct costs were then compared with actual reimbursements received for those treatments. Additionally, gross operating costs per hour and gross average expenses per pediatric patient were calculated, and that cost was then compared with actual reimbursement.
The mission to preferentially treat pediatric patients involves accepting a loss for one-third of pediatric patients before allocating any overhead. After averaging gross expenses over total operating hours, 60% of the pediatric patients were found to be treated at a net loss.
Given insurance constraints and unique costs associated with the pediatric population, PBT centers devoted to children should not be expected to be markedly profitable. For centers that do choose to accept pediatric patients, those patients must be balanced with patients producing higher net reimbursement.
质子束治疗(PBT)是美国最昂贵的放射治疗形式。尽管尚无出版物涉及质子束治疗中心针对儿科患者的实际成本,但质子束治疗在儿科患者中的应用已被模拟出明显优势。儿科病例需要更长的治疗时间,更多的工作人员,且供应和设备成本更高。除了治疗费用更高外,作者所在中心的儿科患者以医疗补助作为主要保险的比例也高于成人。在过去两年中,该中心21岁以下的儿科患者占总治疗患者的32%。作者介绍了他们在质子束治疗环境中治疗大量儿童的成本经验。
在获得当地机构审查委员会的批准后,对2011年11月1日至2013年10月31日期间开始治疗的21岁及以下患者的数据进行了审查。计算所使用设备和用品的直接费用、麻醉计费、人员配备以及直接运营成本(质子束),以确定治疗的直接成本。然后将这些直接成本与这些治疗实际获得的报销进行比较。此外,计算了每小时的总运营成本和每位儿科患者的总平均费用,并将该成本与实际报销进行比较。
优先治疗儿科患者的任务意味着在分摊任何间接费用之前,有三分之一的儿科患者会出现亏损。在将总费用平均分摊到总运营小时数后,发现60%的儿科患者治疗出现净亏损。
考虑到保险限制以及儿科人群的独特成本,致力于治疗儿童的质子束治疗中心不应期望有显著的盈利。对于确实选择接收儿科患者的中心,必须将这些患者与产生更高净报销的患者进行平衡。